ArticleJournal of medical biochemistry2026
Development and validation of a risk prediction model for hepatorenal syndrome in hepatic failure patients based on glucose-6-phosphate dehydrogenase and hepatic and renal function biochemical parameters.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop and validate a novel risk prediction model for hepatorenal syndrome (HRS) in hepatic failure (HF) patients by integrating glucose-6-phosphate dehydrogenase (G6PD) activity with conventional hepatic and renal function biochemical parameters, thereby enhancing early HRS detection beyond the limitations of traditional indicators. Methods: We performed a retrospective analysis of 264 HF patients (82 with HRS, 182 without HRS) hospitalized between July 2020 and July 2022. G6PD levels and standard hepatic/renal function biochemical parameters (ALT, AST, TBil, GGT, BUN, Scr, UA, and CysC) were assessed. Key predictors were identified via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and a multivariate logistic regression model was developed. Model performance was evaluated using receiver operating characteristic (ROC) analysis, with internal validation conducted through a 70:30 training-validation split. Results: HRS patients exhibited significantly lower G6PD activity than non-HRS HF controls (P < 0.05). While G6PD alone showed moderate predictive value (AUC = 0.742; sensitivity 59.76%, specificity 79.12%), the composite model integrating G6PD, GGT, UA, Scr, and CysC demonstrated markedly improved discrimination, achieving AUCs of 0.960 (95%CI: 0.931-0.990) in the training cohort and 0.957 (95%CI: 0.913-1.000) in the validation cohort with both sensitivity and specificity outperforming individual indicators. The derived risk equation was Combined testing Youden = -17.038 + -0.116 x G6PD + 0.102 x GGT + 0.016 x UA + 0.040 x Scr + 3.760 x CysC. Conclusions: The integration of G6PD with hepatic and renal function biochemical parameters significantly enhances HRS risk stratification in HF patients. This validated tool offers superior sensitivity and specificity for the early identification of HRS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.